Is This the Right Time to Hold EW Stock in Your Portfolio?

Impact · against what's priced in

The article provides a balanced view of Edwards Lifesciences, noting strong growth momentum in TMTT and TAVR alongside systemic risks from tariffs and currency fluctuations. Because these catalysts and headwinds are already reflected in the stock's valuation relative to its peers, the news is not a price driver.

EW+0.10

No priced-in read yet

In context

Strong TMTT growth and a favorable earnings yield relative to the industry are offset by risks from tariff uncertainty and currency headwinds.

Read from the article alone

• earnings▲23%
• healthcare
• EW
• currency
• medical devices
• share repurchases
• tariffs
• tavr
• tmtt